As I thought about an interesting trade idea this weekend, I decided to focus on a low-priced small biopharma concern that trades right around $5 a shareLike most small biotech/biopharma names that haven't achieved profitability yet, shares of Ocular Therapeutix (OCUL) have been hammered over the past couple of quarters as high-beta sectors have ...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.